Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment

Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and...

Full description

Bibliographic Details
Main Authors: Akira Nakao, Osamu Hiranuma, Junji Uchino, Chikara Sakaguchi, Tomoyuki Araya, Noriya Hiraoka, Tamotsu Ishizuka, Takayuki Takeda, Masayuki Kawasaki, Yasuhiro Goto, Hisao Imai, Noboru Hattori, Keita Nakatomi, Hidetaka Uramoto, Kiyoaki Uryu, Minoru Fukuda, Yasuki Uchida, Toshihide Yokoyama, Masaya Akai, Tadashi Mio, Seiji Nagashima, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Takako Mouri, Tadaaki Yamada, Kenichi Yoshimura, Masaki Fujita, Koichi Takayama
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Journal of Clinical Medicine
Subjects:
non-small cell lung cancer
EGFR-TKI
T790M
osimertinib
Online Access:https://www.mdpi.com/2077-0383/9/6/1762

Internet

https://www.mdpi.com/2077-0383/9/6/1762

Similar Items